PolyPeptide Laboratories Group Acquires NeoMPS
News Nov 20, 2007
PolyPeptide Laboratories Group has announced its acquisition of peptide manufacturing Group NeoMPS from Isochem, the fine chemicals subsidiary of the French Groupe SNPE. NeoMPS operates facilities in France (Strasbourg) and the United States (San Diego).
The acquisition bolsters PolyPeptide Laboratories’ manufacturing capacity and capabilities, from small-scale custom peptides for research to large-scale peptides for therapeutic applications. Such capabilities complement the Group’s long-established core strength in GMP manufacturing, and will help service a range of projects from conception through commercialization. NeoMPS also manufactures cosmetic peptides and brings an extensive catalog business to the PolyPeptide Laboratories Group.
“The addition of NeoMPS to the PolyPeptide Laboratories Group is a great fit, and offers customers of both companies an even more comprehensive range of services for every stage of development,” said Jane Salik, CEO of PolyPeptide Laboratories Group.
“With this acquisition, we are expanding our capacity to meet the needs of customers who demand the most robust, scalable and cost efficient peptide manufacturing available,” Salik said.
NeoMPS CEO Serge Plaue added, “By joining PolyPeptide Laboratories Group, we are able to offer customers our combined, highly complementary experience and capabilities. Together, we can provide an unparalleled range of services.”
With the NeoMPS acquisition, PolyPeptide Laboratories Group operates GMP facilities in the United States (Torrance and San Diego, California), France (Strasbourg), Denmark (Hillerod) and Sweden (Malmo). Ongoing expansions in Malmo, Torrance, and Strasbourg are continuing as planned. The Group is also constructing a new, soon-to-be-launched GMP facility in Mumbai, India that will be focused on generic peptides.
The acquisition will not affect ongoing activities at the NeoMPS facilities in Strasbourg and San Diego. Harmonization of procedures to ensure consistency, continuity and quality within the expanded PolyPeptide Laboratories Group will be implemented in the coming months.